Skip to main content
Equibles

Sarah

Analyst

Guggenheim Securities

Equibles does not estimate personal net worth.

About Sarah

Sarah is recorded as Analyst at Guggenheim Securities. Sarah has spoken on 1 earnings call and 2 other investor events across 3 companies, most recently for Revolution Medicines, Inc. on May 31, 2026. Those appearances were for Revolution Medicines, Inc. (RVMD), Genmab A/S (GMAB) and Arcbest Corp (ARCB). The companies whose calls Sarah spoke on are classified in the Healthcare and Industrials sectors.

Sarah on recent calls

“Continuing on the theme of potential expansion opportunities for directs and RASIB, I guess wanted to ask if you had any updated comments on plans in frontline lung.”
Analyst — Guggenheim Securities, Revolution Medicines Conference Call ·
“I'm from Michael Schmidt from Guggenheim. Thanks for taking my question. I wanted to quickly circle back to VINAS, if you could comment on the size of the opportunities for VINAS, both in and outside of Dynon, including in the ongoing phase two.”
Analyst — Guggenheim, Genmab A/S Q4 FY2025 Earnings Call ·
“We could see a lot of upside with managed. and then on the truckload side i mean you've heard us speak a lot today about the efficiency improvement our investment in tech has in our pilots that we have going on in tech inbound call automation automated appointment scheduling automated load building all of those things…”
ArcBest 2025 Investor Day ·

Affiliation history

  • Guggenheim Securities

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity